PTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Wall Street climbs as Broadcom and other chipmakers rally
- Oil prices little changed as Saudi cuts prices, OPEC+ boosts target
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Dara Khosrowshahi steps down from Grab Holdings board
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Wall Street climbs as Broadcom and other chipmakers rally
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
PTC Therapeutics (PTCT) PT Lowered to $46 at RBC Capital
November 6, 2018 6:46 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $46.00 (from $51.00) while maintaining an Outperform rating.
"3Q optics were unfavorable, given the Translarna miss, Emflaza guidance adjustment, and increased spend, and we could see shares trade off modestly," Abrahams commented.
... MorePTC Therapeutics (PTCT) Misses Q3 EPS by 66c, Revenues Miss; Lowers FY18 Revenue Outlook
November 5, 2018 4:38 PM ESTPTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.06), $0.66 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $53.59 million versus the consensus estimate of $70.9 million.
"We have been aggressively pursuing our vision to build a leading, fully integrated,... More
